Pancreatic Cancer Research

ResearcherNagoya University HospitalActive in the last 2 years

Tomoki Ebata

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0002-8247-7050; OpenAlex author ID A5060579946. Sources: OpenAlex.

Their work

Papers
14 (first author 2, last author 6)
Trials
0
Grants
0
Labs led
1
Collaborators
39
Papers, trials and grants by year

2012: 1 paper · 2013: none · 2014: none · 2015: none · 2016: 1 paper · 2017: 1 paper · 2018: none · 2019: none · 2020: none · 2021: none · 2022: 1 paper · 2023: 3 papers · 2024: 2 papers · 2025: 3 papers · 2026: 2 papers

Papers 14

  1. Clinical Outcomes of Gemcitabine Plus Nab-Paclitaxel-Based Chemoradiotherapy in a Multidisciplinary Treatment Strategy for Locally Advanced Pancreatic Cancer (… Co-author DOI 10.1002/ijc.70801↗
  2. Neoadjuvant Chemotherapy (FOLFIRINOX or Gemcitabine With Nab-Paclitaxel) for Borderline-Resectable Pancreatic Cancer: Long-Term Results of a Randomized Control… Last author DOI 10.1002/jhbp.70150↗
  3. Close correlation between patients' positive mood and postoperative complication burden in hepato-biliary-pancreatic cancer: a prospective comparative cohort t… Last author DOI 10.1016/j.hpb.2025.07.015↗
  4. FUT2 and FUT3-specific normalization of DUPAN-2 and carbohydrate antigen 19-9 in preoperative therapy for pancreatic cancer: multicentre retrospective study (G… Co-author DOI 10.1093/bjs/znaf049↗
  5. FAM111B Suppression Enhances Sensitivity to Gemcitabine in Pancreatic Cancer Through Intracellular pH Regulation. Last author DOI 10.1111/cas.70212↗
  6. Trefoil factor 1 suppresses stemness and enhances chemosensitivity of pancreatic cancer. Last author DOI 10.1002/cam4.7395↗
  7. Impact of sarcopenia on biliary drainage during neoadjuvant therapy for pancreatic cancer. Co-author DOI 10.5946/ce.2022.278↗
  8. Impact of skeletal muscle mass on the prognosis of patients undergoing neoadjuvant chemotherapy for resectable or borderline resectable pancreatic cancer. Last author DOI 10.1007/s10147-023-02321-1↗
  9. Antitumor Effects of Deep Ultraviolet Irradiation for Pancreatic Cancer. Co-author DOI 10.21873/anticanres.16198↗
  10. Cyclodextrin Conjugated α-Bisabolol Suppresses FAK Phosphorylation and Induces Apoptosis in Pancreatic Cancer. Co-author DOI 10.21873/anticanres.16245↗
  11. Results of a Phase II Study on the Use of Neoadjuvant Chemotherapy (FOLFIRINOX or GEM/nab-PTX) for Borderline-resectable Pancreatic Cancer (NUPAT-01). Last author DOI 10.1097/sla.0000000000005430↗
  12. Trefoil factor family 1 expression in the invasion front is a poor prognostic factor associated with lymph node metastasis in pancreatic cancer. Co-author DOI 10.1016/j.pan.2017.07.188↗
  13. Optimal dose of gemcitabine for the treatment of biliary tract or pancreatic cancer in patients with liver dysfunction. First author DOI 10.1111/cas.12851↗
  14. [Borderline resectable pancreatic cancer - a definition and effective treatment strategy]. First author PMID 22421757↗

Closest collaborators

The 25 strongest of 39 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Junpei Yamaguchi · 12 shared papers, 2017–2026 · strength 2.27
  2. Yukihiro Yokoyama · 11 shared papers, 2012–2026 · strength 1.86
  3. Masaki Sunagawa · 7 shared papers, 2017–2025 · strength 1.26
  4. Shunsuke Onoe · 6 shared papers, 2023–2025 · strength 1.16
  5. Toshio Kokuryo · 7 shared papers, 2012–2025 · strength 1.07
  6. Osamu Maeda · 5 shared papers, 2016–2026 · strength 0.90
  7. Hiroki Kawashima · 4 shared papers, 2022–2026 · strength 0.84
  8. Yasuhiro Kodera · 4 shared papers, 2022–2025 · strength 0.70
  9. Takuya Ishikawa · 3 shared papers, 2022–2026 · strength 0.62
  10. Tsutomu Fujii · 3 shared papers, 2022–2026 · strength 0.56
  11. Shoji Kawakatsu · 2 shared papers, 2025 · strength 0.47
  12. Suguru Yamada · 2 shared papers, 2022–2026 · strength 0.43
  13. Haruyoshi Tanaka · 2 shared papers, 2025–2026 · strength 0.42
  14. Nobuhiko Nakagawa · 2 shared papers, 2025–2026 · strength 0.42
  15. Taisuke Baba · 2 shared papers, 2023–2025 · strength 0.40
  16. Eizaburo Ohno · 2 shared papers, 2022–2024 · strength 0.33
  17. Kimitoshi Yamazaki · 2 shared papers, 2023 · strength 0.31
  18. Masato Nagino · 2 shared papers, 2023 · strength 0.31
  19. Motonobu Nishimura · 1 shared paper, 2025 · strength 0.25
  20. Mitsuro Kanda · 1 shared paper, 2026 · strength 0.22
  21. Masamichi Hayashi · 1 shared paper, 2026 · strength 0.22
  22. Shinji Naganawa · 1 shared paper, 2026 · strength 0.22
  23. Hironori Yamada · 1 shared paper, 2026 · strength 0.22
  24. Tomohisa Otsu · 1 shared paper, 2025 · strength 0.20
  25. Masaya Suenaga · 1 shared paper, 2025 · strength 0.20

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.